Alex Goldberg

ArQule Inc. (NASDAQ:ARQL) and Expedia Inc. (NASDAQ:EXPE) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/17/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding ArQule Inc. (NASDAQ:ARQL) and Expedia Inc. (NASDAQ:EXPE).

ArQule Inc. (NASDAQ:ARQL) a clinical-stage biotechnology company that engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes is currently up (+6.78%) on 3,995,871 shares traded after ArQule Provided Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib. ArQule Inc. (NASDAQ:ARQL) is currently up (+52.88%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about ArQule Inc. (NASDAQ:ARQL)

Expedia Inc. (NASDAQ:EXPE) together with its subsidiaries, operates as an online travel company in the United States and internationally is currently up (+2.98%) on 2,814,508 shares traded. Expedia Inc. (NASDAQ:EXPE) is currently up (+57.69%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Expedia Inc. (NASDAQ:EXPE)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com